Payment overview · 2025
General Payments
$1,723.02
79 reported records · 17 companies
Healthcare provider profile · identity verified
Daisy Andaleon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PLEASANT PRAIRIE, WI · NPI 1093723413
Verified facts
What the public records show
CMS Open Payments records show Daisy Andaleon, M.D. received $1,723.02 in general payments during 2025 across 79 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.33 | 14.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $247.92 | 14.4% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.63 | 11.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.09 | 9.1% | 7 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $98.56 | 5.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $97.93 | 5.7% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $93.25 | 5.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.46 | 5.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $79.77 | 4.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.38 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $71.49 | 4.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.01 | 4.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.09 | 3.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.61 | 3.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.93 | 2.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.15 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.42 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,723.02 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $180.46 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $156.46 | 9 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $98.56 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $97.93 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.71 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $93.25 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $91.46 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $89.91 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $89.91 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $89.91 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $85.66 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.77 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.38 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.18 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.09 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.61 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.32 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 75 |
| Metformin Hcl | Metformin Hcl | 350 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 85 |
| Gabapentin | Gabapentin | 309 | 65 |
| Losartan Potassium | Losartan Potassium | 294 | 86 |
| Lisinopril | Lisinopril | 253 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 58 |
| Carvedilol | Carvedilol | 215 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 49 |
| Montelukast Sodium | Montelukast Sodium | 174 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 57 |
| Famotidine | Famotidine | 168 | 48 |
| Omeprazole | Omeprazole | 168 | 44 |
| Potassium Chloride | Potassium Chloride | 156 | 45 |
| Furosemide | Furosemide | 155 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 48 |
| Jardiance | Empagliflozin | 137 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 31 |
| Glimepiride | Glimepiride | 124 | 31 |
| Tramadol Hcl | Tramadol Hcl | 123 | 33 |
| Simvastatin | Simvastatin | 107 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 95 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 23 |
| Farxiga | Dapagliflozin Propanediol | 83 | 16 |
| Alendronate Sodium | Alendronate Sodium | 82 | 29 |
| Allopurinol | Allopurinol | 82 | 23 |
| Eliquis | Apixaban | 80 | 23 |
| Fenofibrate | Fenofibrate | 79 | 19 |
| Alprazolam | Alprazolam | 67 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 18 |
| Cephalexin | Cephalexin | 64 | 47 |
| Ibuprofen | Ibuprofen | 63 | 22 |
| Meclizine Hcl | Meclizine Hcl | 63 | 22 |
| Meloxicam | Meloxicam | 62 | 11 |
| Spironolactone | Spironolactone | 56 | 11 |
| Glipizide | Glipizide | 54 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 37 |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Amoxicillin | Amoxicillin | 48 | 35 |
| Sertraline Hcl | Sertraline Hcl | 47 | 12 |
| Mupirocin | Mupirocin | 46 | 26 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 18 |
| Ozempic | Semaglutide | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 11 |
| Glipizide Er | Glipizide | 42 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 15 |
| Azelastine Hcl | Azelastine Hcl | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 22 |
| Donepezil Hcl | Donepezil Hcl | 38 | 12 |
| Linzess | Linaclotide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Tradjenta | Linagliptin | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Prednisone | Prednisone | 24 | 11 |
| Fluconazole | Fluconazole | 23 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,723.02 · 79 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error